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Purpose: To describe a case of choroidal neovascularization (CNV) in a female diagnosed 
with Beals–Hecht syndrome.
Methods: A retrospective, interventional case is described in a 26-year-old female complaining 
of metamorphopsia and visual loss in her left eye (counting fingers). The fluorescein angiogram 
and the optical coherence tomography supported the diagnosis of CNV . Intravitreal ranibizumab 
was administered.
Results: After the third intravitreal ranibizumab, her visual acuity improved to 0.8 and the 
morphology of the macular area was restored.
Conclusions: To our knowledge this is the first report of CNV in Beals–Hecht syndrome treated 
with ranibizumab. Self-monitoring by periodically performing Amsler grid test is strongly 
recommended in these patients in order to achieve an early diagnosis of eventual CNV and 
avoid visual acuity loss.
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Introduction
Beals–Hecht syndrome is an autosomal dominantly inherited connective tissue disorder 
caused by a mutation in the fibrillin-2 gene (FBN2) in 5q23.1 Although the clinical fea-
tures can be similar to Marfan syndrome, multiple joint contractures and crumpled ears 
in the absence of significant aortic root dilatation are characteristic of Beals syndrome 
and rarely found in Marfan syndrome.2 General ocular complications are estimated to 
be present in 20% of patients with Beals syndrome or congenital contractural arach-
nodactyly (CCA).3 Whereas ectopia lentis is very rare in Beals Syndrome, the typical 
ophthalmic features include blue sclera, axial myopia, cataract, lens coloboma, cilliary 
body hyoplasia, and glaucoma.3
Case report
We describe a case of a 27-year-old woman who attended our Emergency Department 
complaining of sudden metamorphopsia and visual acuity (VA) loss in her left eye 
(LE). She referred a similar episode 4 years before presentation resulting in visual loss 
in her right eye (RE). Best-corrected visual acuity (BCVA) measured 0.16 RE and 0.4 
LE. Systemic examination showed marfanoid habit, scoliosis, crumpled ears, and CCA 
(Figure 1). The patient had been recently diagnosed with Beals–Hecht syndrome after 
genetic testing. Ocular findings included axial myopia (axial length: 27,76 mm RE and Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Figure 1 (A–C) Typical contractural aracnodactylia in Beals syndrome (A, B) and 
joint hypermobility (C).
Figure 2 Fundus examination. A) Retinography showing disciform-like scar RE and juxtafoveal fibrovascular proliferation LE. B) Angiogram showing predominantly classic 
choroidal neovascular membrane (CNV). C) spectral-domain optical coherence tomography (sD-OCT) images showing the subretinal choroidal neovascular membrane 
inducing loss of foveal anatomy. D) sD-OCT images showing complete resolution of the retinal edema and normalization of the foveal anatomy after three monthly 
intravitreal ranibizumab injections.
27,94 mm LE), blue sclera, and fundus examination showed a 
disciform-like scar RE and a juxtafoveal fibrovascular prolif-
eration LE. Fluorescein angiography confirmed the presence 
of a predominantly classic choroidal neovascular membrane 
(CNV) LE, which induced intraretinal edema with foveal pit 
loss in the spectral-domain optical coherence tomography 
(Cirrus High-Definition OCT, Carl Zeiss Meditec, Dublin, 
CA, USA) images (Figure 2). With the formal diagnosis of 
a disciform maculopathy RE as described in Ehlers–Danlos 
disease,4 and CNV LE, the patient received three monthly 
intravitreal injections of ranibizumab (Lucentis, Genentech, 
South San Francisco, CA, USA). One month after the third 
injection the BCVA measured 0.8 LE and the OCT showed 
complete resolution of the retinal edema and normalization of 
the foveal anatomy (Figure 2). This outcome remained stable 
through an 8-months follow-up without further intravitreal 
retreatments.
Discussion
To our knowledge this is the first report of CNV in 
  Beals–Hecht syndrome treated with ranibizumab. Why this 
case is more likely to be due to the collagen disease rather 
than to axial myopia? On the one hand, the appearance of the 
RE disciform scar is unusual for myopic CNV , but it has been 
described in the context of Ehlers–Danlos disease, caused 
by collagen disorder;4 on the other hand, LE did not show 
a significant myopic choroidopathy and in addition lacquer 
crack lesions were only evidence between inferior vascular 
arcades but not within the posterior pole.
Ranibizumab has been widely used for myopic CNV 
with very good results, with fewer retreatments needed as 
compared to CNV due to age-related macular degeneration.5,6 
In the case we report, the clinical and morphological response 
to intravitreal ranibizumab was excellent resulting in long-
term normalization of the foveal contour and improvement 
in visual acuity.
From our point of view, as far as onset of metamorphop-
sia may be an initial symptom of CNV, self-monitoring 
by periodically performing Amsler grid test is strongly Clinical Ophthalmology
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recommended in these patients in order to achieve an early 
diagnosis and avoid VA loss.
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